ClinicalTrials.gg
CompletedNCT04764695HMUpdated Dec 6, 2024

Body Composition and Nutritional Status in Pediatric Patients With Hematological Malignancies

An interventional study of D2O dilution technique in Childhood Cancer, Child Malnutrition and Childhood Obesity, sponsored by Universidad de Sonora. Completed at 1 site in Mexico. Open to participants aged 2 Years to 14 Years. Per ClinicalTrials.gov, last updated 2024-12-06.

Sponsored by Universidad de Sonora · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
38
Allocation
Not applicable
Ages
2 Years to 14 Years
Sex
All
01

Study summary

Introduction: Annually 400,000 children are diagnosed with cancer in the world. Approximately 90% live in low/middle-income countries, with survival rates of 10-30%. In Mexico, children and adolescents' hospital admissions for cancer are mainly leukemias (46%), being acute lymphoblastic leukemia (ALL) the most common. Half of ALL patients have an altered nutritional status at the time of diagnosis. Nutritional assessment is performed using conventional anthropometric measures, which are not sensitive to changes in fat-free mass and fat mass (FFM and FFM). Our objective is to evaluate the body composition and nutritional status in pediatric patients with HM. This is a pre-test/post-test clinical trial. Children 2-14 y olds diagnosed with leukemia, myeloma and lymphoma in any stage of oncological treatment will participate. The nutritional status will be evaluated using questionnaires and body composition. Measurements will occur at the enrrollment of the study and 6 months after.

Read the detailed description

JUSTIFICATION Nutritional assessment of cancer patients is usually performed using conventional anthropometric techniques, which are not sensitive to short-term changes and do not reflect changes in the FFM, FM, and hydration status. Assessing body composition using reference techniques such as deuterium oxide dilution (DOD), and also using field methods (BIA and anthropometry), which are more accessible in clinical practice, can detect short-term changes in children and adolescents with HM.

In cancer patients, protein and muscle stores are frequently affected; an increase in FM and a decrease in FFM were observed within the first 6 months of antineoplastic treatment. The DOD technique identifies three compartments (total body water, FFM, and FM). Similar changes in body composition are seen in patients with breast cancer; the work carried out by Limón-Miró et al; where it was observed that an individualized nutritional intervention preserved FFM while reducing FM, both associated with quality of life and survival in breast cancer patients. This highlights the importance of specialized nutritional and body composition evaluations in the comprehensive treatment of cancer patients; in children and adolescents with HM, monitoring body composition combined with a nutrition intervention, could reduce the deterioration of FFM and provide a window to assess prognosis, clinical outcome, and survival of HM pediatric patients.

HYPOTHESES The body composition (fat and fat-free mass) and nutritional status of pediatric patients with HM in active treatment will be different at the beginning vs. the end of the study (6 months), in addition to showing differences against the healthy reference population.

GENERAL OBJECTIVE To evaluate changes in body composition and nutritional status in pediatric patients with HM under active treatment.

SPECIFIC OBJECTIVES

  • To evaluate nutritional status using anthropometric and dietary indicators at the beginning and 6 months after the intervention.
  • To assess fat mass and fat-free mass using reference and field techniques, at baseline and 6 months after the intervention.
  • To establish a protocol on monitoring nutrition status and body composition that can be applied routinely in clinical practice.

METHODOLOGY Study design This is a pre-test/post-test design. Children from 2 to 14 years old with a diagnosis of HM two areas of Mexico (Hermosillo, Sonora / Guadalajara, Jalisco) will participate.

Sample size: To determine the sample size, we will work on the assumptions of a standard deviation (SD) of Fat-Free Mass (FFM) of 2.19 Kg, with a Variance of 4.8 Kg, a Zα of 1.96 for a p = 0.05, with a mean difference (Ԁ) of 1 Kg. The sample size was calculated considering the Beta error of 20% (B = 0.84), depending on the availability of the number of patients who agreed to participate, as well as those excluded by established criteria. Based on the data mentioned, the estimated sample size calculation is 38 participants, as detailed in the following equation.

N = ((Zα + Zβ) \^ 2 〖(DE)〗 \^ 2) / 〖(d)〗 \^ 2 = 38 participants Clinical record: The principles of the Official Mexican Norm (NOM) NOM-024-SSA3-201 will be followed, which establishes the functional objectives and functionalities that must be followed in the use of electronic clinical records. For this purpose, a confidential file number will be assigned, so that when analyzing the biological samples or data collected in the field, no access will be given to the names, address, telephone number, or related information that may be exposed to the participant.

Screening: Predictive screening will be used for the "Nutrition Screening Tool For Childhood Cancer (SCAN)" which consists of 6 questions. This tool identifies the need for a nutritional intervention according to the symptoms of the patients who classify at risk of malnutrition. Screening should be applied to all study subjects at each consultation or weekly to patients who are hospitalized since they are at high risk of malnutrition at the time of diagnosis and increases in the stages of treatment. The Lansky pediatric scale will also be applied, which allows evaluating the general condition of the patient, representing the degree of autonomy in the activities of daily life. In addition, the PedsQL Cancer Module © will be used, which is derived from the Pediatric Quality of Life Questionnaire (PedsQL), which is a generic instrument designed for children and parents to assess the quality of life as a self-report.

Dietary evaluation: The ENSANUT frequency questionnaire will be applied for the respective age groups: preschoolers, schoolchildren, and adolescents.

Anthropometry Weight and height: Body weight will be measured (electronic scale with 0.150 + 0.05 kg scales) or child scale (0-20 kg). Height will be measured by SECA stadiometers or infantometers, as required to the nearest 0.1 cm.

Mid-upper arm circumference (MUAC): This measure allows the identification of malnutrition in children under 5 years of age without taking weight, height, and age, by measuring the arm circumference at its midpoint.

Tricipital skinfold (TSF): With the participant standing, with the feet together, the shoulders relaxed and the arms hanging relaxed at the sides. The examiner will stand on the right side of the patient and place the top point on the back surface of the arm in the same area as the midpoint marked for the arm circumference. The skin fold of the skin and subcutaneous adipose tissue will be gently grasped with the thumb and index finger, approximately 1.0 cm above the point where the skin was scored, with the skin fold parallel to the longitudinal axis of the upper arm. The jaws of the calipers will be placed at the level that the skin was marked, these should be positioned perpendicular to the length of the fold. The skinfold will be held gently and the skinfold thickness will be measured to the nearest 1mm.

Waist circumference (WC): The waist circumference will be measured with a retractable tape at the level of the umbilical scar in a standing position and after exhaling.

All measurements will be processed by the Anthro software of the World Health Organization, for the calculation of nutritional indices such as Z score of weight/age, height/age, and weight/height in children \<60 months, BMI-age- sex, and height/age in children> 60 months. A physical examination will be performed to observe signs of malnutrition (loss of subcutaneous fat, muscle wasting, edema, etc.).

Body composition Deuterium oxide dilution: Total body water will be measured by dilution of deuterium oxide (DOD) using Fourier transform infrared spectroscopy (FTIR) with a saliva sample. The doses of deuterium will be those recommended for field studies by the International Atomic Energy Agency (an amount that does not represent a risk for minors).

The measurement will be taken once the patient has gone to the bathroom, sterile material will be used taking care of the cleanliness and safety of the personnel in charge of the measurement. A pre-dose saliva sample will be taken, once the dose is calculated by the patient's weight, the DOD will be administered, this should be taken with syringe to avoid spilling the dose. After 3 hours, a post-dose saliva sample will be taken, at the time of calculation, it will be taken into account if the patient ingested extra fluids.

Electrical bioimpedance (BIA): BIA is considered a simple, fast, and non-invasive technique that allows the estimation of total body water (TBW), fat-free mass (FFM), and, by difference, fat mass (FM). The patient must be in the supine position at the time of measurement for at least 5 minutes before starting. 4 electrodes will be placed on its left ends, two on the hand and two on the foot, 5 cm away from each other, a current of 50 mHz is administered, then a resistance and reactance reading is taken to obtain the result of the test. impedance, following the standardized methodology.

For the study population, it is proposed to use the equation validated in the child population proposed by Ramírez E., et al. In this way, when knowing the FFM, the FM will be estimated by difference with the total body weight.

FFM(kg) = 0.661 x Ht2 / R + 0.200 x Wt - 0.320 Where Ht is height in cm squared, R is resistance, and Wt is weight in kg. Individualized nutritional intervention

Statistic analysis Descriptive statistics will be used using NCSS v11. To evaluate the effectiveness of the intervention, the t-student test or non-parametric tests will be performed depending on the distribution of the data. For BIA an algorithm will be used to predict total body water for the calculation of FFM and FM compared to the results of dilution with deuterium. Intention-to-treat analysis will also be performed, which should be seen more as a global strategy for the design, execution, and analysis of clinical trials, rather than solely as an alternative analysis.

02

Conditions studied

  • Childhood Cancer
  • Child Malnutrition
  • Childhood Obesity

Keywords

  • Children
  • Body Composition
  • Nutrition
03

In context

Neoplasms

10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.

This study's enrollment of 38 is below the median of 60 across 7,703 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Universidad de Sonora is the lead sponsor of 15 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients in remission stage (4 - 6 weeks)
  • > 6 months and sufficient general conditions according to scales (Lansky ≥ 50 points for children \<16 years)
  • Histopathological/molecular clinical confirmation of the HM diagnosis
  • Signature of the consent by the relative or legal guardian of the patient and as well as the consent informed by the patient.

Exclusion criteria

Exclusion Criteria:

  • Pathological conditions that can alter body composition (diabetes, hypothyroidism, among others)
  • Patients with sepsis that causes hemodynamic compromise and cannot be evaluated
  • Severely ill patients unable to participate in baseline measurements
  • patients
  • Patients with developmental problems of a genetic order as well as innate errors of metabolism
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Patients diagnosed with HM

    As it is a pre-test / post-test design, the child himself will be the control at the end of the study. Additionally, children without ALL of the same age and sex will be taken as reference. The potential of including paired measurements against healthy children for external control is analyzed.

    Diagnostic Test: D2O dilution technique

Interventions

  • Diagnostic testD2O dilution technique

    Body composition will be measured with the deuterium dilution technique and electrical bioimpedance, as well as anthropometric indicators at the beginning and 6 months later.

06

What researchers measure

Primary outcomes

  1. FFM 1

    Fat free mass in kilograms (Kg)

    Time frame: at enrrollment

  2. FFM 2

    Fat free mass in kilograms (Kg)

    Time frame: 6 months

  3. FM 1

    Fat mass in kilograms (Kg)

    Time frame: at enrrollment

  4. FM 2

    Fat mass in kilograms (Kg)

    Time frame: 6 months

  5. TBW 1

    Total body water in kilograms (Kg)

    Time frame: at enrrollment

  6. TBW 2

    Total body water in kilograms (Kg)

    Time frame: 6 months

Secondary outcomes

  1. BMI

    Body mass index for age in Kg/m\^2

    Time frame: through study duration, an average of 6 months, once a month

  2. Weight

    Weight in kilograms (Kg)

    Time frame: through study duration, an average of 6 months, once a month

  3. MUAC

    Mid arm muscle circumference in centimeters (cm)

    Time frame: through study duration, an average of 6 months, once a month

  4. Tricep skin fold (TSK)

    Tricep skinfold in milimeters (mm)

    Time frame: through study duration, an average of 6 months, once a month

  5. WC

    Waist circumference in centimeters (cm)

    Time frame: through study duration, an average of 6 months, once a month

  6. R

    Resistance in Ohms

    Time frame: through study duration, an average of 6 months, once a month

  7. Xc

    Reactance in Ohms

    Time frame: through study duration, an average of 6 months, once a month

  8. Height

    Height in cm

    Time frame: through study duration, an average of 6 months, once a month

07

Study locations

1 site
  • Universidad de Sonora
    Hermosillo, Sonora 83000, Mexico
08

References and documents

Publications

  • Ward EJ, Henry LM, Friend AJ, Wilkins S, Phillips RS. Nutritional support in children and young people with cancer undergoing chemotherapy. Cochrane Database Syst Rev. 2015 Aug 24;2015(8):CD003298. doi: 10.1002/14651858.CD003298.pub3. PubMed 26301790 ↗
  • Cohen JE, Wakefield CE, Cohn RJ. Nutritional interventions for survivors of childhood cancer. Cochrane Database Syst Rev. 2016 Aug 22;2016(8):CD009678. doi: 10.1002/14651858.CD009678.pub2. PubMed 27545902 ↗
  • Francis DK, Smith J, Saljuqi T, Watling RM. Oral protein calorie supplementation for children with chronic disease. Cochrane Database Syst Rev. 2015 May 27;2015(5):CD001914. doi: 10.1002/14651858.CD001914.pub2. PubMed 26014160 ↗
  • Ladas EJ, Orjuela M, Stevenson K, Cole PD, Lin M, Athale UH, Clavell LA, Leclerc JM, Michon B, Schorin MA, Welch JG, Asselin BL, Sallan SE, Silverman LB, Kelly KM. Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study. Nutrition. 2016 Oct;32(10):1103-1109.e1. doi: 10.1016/j.nut.2016.03.014. Epub 2016 Mar 28. PubMed 27318855 ↗
  • Ramirez E, Valencia ME, Moya-Camarena SY, Aleman-Mateo H, Mendez RO. Four-compartment model and validation of deuterium dilution technique to estimate fat-free mass in Mexican youth. Nutrition. 2009 Feb;25(2):194-9. doi: 10.1016/j.nut.2008.08.007. Epub 2008 Oct 23. PubMed 18947978 ↗
  • Yang HR, Choi HS. A prospective study on changes in body composition and fat percentage during the first year of cancer treatment in children. Nutr Res Pract. 2019 Jun;13(3):214-221. doi: 10.4162/nrp.2019.13.3.214. Epub 2019 Mar 13. PubMed 31214289 ↗
  • De Palo T, Messina G, Edefonti A, Perfumo F, Pisanello L, Peruzzi L, Di Iorio B, Mignozzi M, Vienna A, Conti G, Penza R, Piccoli A. Normal values of the bioelectrical impedance vector in childhood and puberty. Nutrition. 2000 Jun;16(6):417-24. doi: 10.1016/s0899-9007(00)00269-0. PubMed 10869896 ↗
  • Cameron N. Essential anthropometry: Baseline anthropometric methods for human biologists in laboratory and field situations. Am J Hum Biol. 2013 May-Jun;25(3):291-9. doi: 10.1002/ajhb.22388. No abstract available. PubMed 23606226 ↗
  • Jones PJ, Leatherdale ST. Stable isotopes in clinical research: safety reaffirmed. Clin Sci (Lond). 1991 Apr;80(4):277-80. doi: 10.1042/cs0800277. PubMed 1851061 ↗
  • Abrams SA. Assessing mineral metabolism in children using stable isotopes. Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):438-41; discussion 451. doi: 10.1002/pbc.21417. PubMed 18064657 ↗
  • Wauben IP, Atkinson SA, Bradley C, Halton JM, Barr RD. Magnesium absorption using stable isotope tracers in healthy children and children treated for leukemia. Nutrition. 2001 Mar;17(3):221-4. doi: 10.1016/s0899-9007(00)00507-4. PubMed 11312063 ↗
  • Egnell C, Ranta S, Banerjee J, Merker A, Niinimaki R, Lund B, Mogensen PR, Jonsson OG, Vaitkeviciene G, Lepik K, Forslund A, Heyman M, Harila-Saari A. Impact of body mass index on relapse in children with acute lymphoblastic leukemia treated according to Nordic treatment protocols. Eur J Haematol. 2020 Dec;105(6):797-807. doi: 10.1111/ejh.13517. Epub 2020 Sep 20. PubMed 32909636 ↗
  • Brinksma A, Roodbol PF, Sulkers E, Kamps WA, de Bont ES, Boot AM, Burgerhof JG, Tamminga RY, Tissing WJ. Changes in nutritional status in childhood cancer patients: a prospective cohort study. Clin Nutr. 2015 Feb;34(1):66-73. doi: 10.1016/j.clnu.2014.01.013. Epub 2014 Jan 23. PubMed 24508424 ↗
  • Chincesan MI, Marginean CO, Voidazan S. Assessment of Body Composition in a Group of Pediatric Patients With Cancer: A Single Romanian Center Experience. J Pediatr Hematol Oncol. 2016 Oct;38(7):e217-22. doi: 10.1097/MPH.0000000000000586. PubMed 27164536 ↗
  • Jaime-Perez JC, Gonzalez-Llano O, Herrera-Garza JL, Gutierrez-Aguirre H, Vazquez-Garza E, Gomez-Almaguer D. Assessment of nutritional status in children with acute lymphoblastic leukemia in Northern Mexico: A 5-year experience. Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):506-8; discussion 517. doi: 10.1002/pbc.21397. PubMed 18064642 ↗
  • Beer SS, Juarez MD, Vega MW, Canada NL. Pediatric Malnutrition: Putting the New Definition and Standards Into Practice. Nutr Clin Pract. 2015 Oct;30(5):609-24. doi: 10.1177/0884533615600423. Epub 2015 Sep 1. PubMed 26330113 ↗
  • Martinez EE, Smallwood CD, Quinn NL, Ariagno K, Bechard LJ, Duggan CP, Mehta NM. Body Composition in Children with Chronic Illness: Accuracy of Bedside Assessment Techniques. J Pediatr. 2017 Nov;190:56-62. doi: 10.1016/j.jpeds.2017.07.045. PubMed 29144272 ↗
  • den Hoed MA, Pluijm SM, de Groot-Kruseman HA, te Winkel ML, Fiocco M, van den Akker EL, Hoogerbrugge P, van den Berg H, Leeuw JA, Bruin MC, Bresters D, Veerman AJ, Pieters R, van den Heuvel-Eibrink MM. The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia. Haematologica. 2015 Jan;100(1):62-9. doi: 10.3324/haematol.2014.110668. Epub 2014 Oct 10. PubMed 25304613 ↗
  • Loeffen EA, Brinksma A, Miedema KG, de Bock GH, Tissing WJ. Clinical implications of malnutrition in childhood cancer patients--infections and mortality. Support Care Cancer. 2015 Jan;23(1):143-50. doi: 10.1007/s00520-014-2350-9. Epub 2014 Jul 11. PubMed 25011521 ↗
  • Martin-Trejo JA, Nunez-Enriquez JC, Fajardo-Gutierrez A, Medina-Sanson A, Flores-Lujano J, Jimenez-Hernandez E, Amador-Sanchez R, Penaloza-Gonzalez JG, Alvarez-Rodriguez FJ, Bolea-Murga V, Espinosa-Elizondo RM, de Diego Flores-Chapa J, Perez-Saldivar ML, Rodriguez-Zepeda MD, Dorantes-Acosta EM, Nunez-Villegas NN, Velazquez-Avina MM, Torres-Nava JR, Reyes-Zepeda NC, Gonzalez-Bonilla CR, Flores-Villegas LV, Rangel-Lopez A, Rivera-Luna R, Paredes-Aguilera R, Cardenas-Cardos R, Martinez-Avalos A, Gil-Hernandez AE, Duarte-Rodriguez DA, Mejia-Arangure JM. Early mortality in children with acute lymphoblastic leukemia in a developing country: the role of malnutrition at diagnosis. A multicenter cohort MIGICCL study. Leuk Lymphoma. 2017 Apr;58(4):898-908. doi: 10.1080/10428194.2016.1219904. Epub 2016 Aug 26. PubMed 27561220 ↗
  • Mejia-Arangure JM, Bonilla M, Lorenzana R, Juarez-Ocana S, de Reyes G, Perez-Saldivar ML, Gonzalez-Miranda G, Bernaldez-Rios R, Ortiz-Fernandez A, Ortega-Alvarez M, Martinez-Garcia Mdel C, Fajardo-Gutierrez A. Incidence of leukemias in children from El Salvador and Mexico City between 1996 and 2000: population-based data. BMC Cancer. 2005 Apr 4;5:33. doi: 10.1186/1471-2407-5-33. PubMed 15807901 ↗
  • Juarez-Ocana S, Gonzalez-Miranda G, Mejia-Arangure JM, Rendon-Macias ME, Martinez-Garcia Mdel C, Fajardo-Gutierrez A. Frequency of cancer in children residing in Mexico City and treated in the hospitals of the Instituto Mexicano del Seguro Social (1996-2001). BMC Cancer. 2004 Aug 13;4:50. doi: 10.1186/1471-2407-4-50. PubMed 15310396 ↗
  • Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, Carreira H, Spika D, Marcos-Gragera R, Peris-Bonet R, Pineros M, Sant M, Kuehni CE, Murphy MFG, Coleman MP, Allemani C; CONCORD Working Group. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol. 2017 May;4(5):e202-e217. doi: 10.1016/S2352-3026(17)30052-2. Epub 2017 Apr 11. Erratum In: Lancet Haematol. 2017 May;4(5):e201. doi: 10.1016/S2352-3026(17)30067-4. PubMed 28411119 ↗
  • Pritchard-Jones K, Pieters R, Reaman GH, Hjorth L, Downie P, Calaminus G, Naafs-Wilstra MC, Steliarova-Foucher E. Sustaining innovation and improvement in the treatment of childhood cancer: lessons from high-income countries. Lancet Oncol. 2013 Mar;14(3):e95-e103. doi: 10.1016/S1470-2045(13)70010-X. Epub 2013 Feb 20. PubMed 23434338 ↗
  • Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, Hesseling P, Shin HY, Stiller CA; IICC-3 contributors. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017 Jun;18(6):719-731. doi: 10.1016/S1470-2045(17)30186-9. Epub 2017 Apr 11. Erratum In: Lancet Oncol. 2017 Jun;18(6):e301. doi: 10.1016/S1470-2045(17)30369-8. PubMed 28410997 ↗
  • Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008 Nov;11(6):693-700. doi: 10.1097/MCO.0b013e328312c37d. PubMed 18827572 ↗
  • Limon-Miro AT, Lopez-Teros V, Astiazaran-Garcia H. Dietary Guidelines for Breast Cancer Patients: A Critical Review. Adv Nutr. 2017 Jul 14;8(4):613-623. doi: 10.3945/an.116.014423. Print 2017 Jul. PubMed 28710147 ↗
  • Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T. Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin. 2012 Jul-Aug;62(4):243-74. doi: 10.3322/caac.21142. Epub 2012 Apr 26. Erratum In: CA Cancer J Clin. 2013 May;63(3):215. PubMed 22539238 ↗
  • Polyzos SA, Margioris AN. Sarcopenic obesity. Hormones (Athens). 2018 Sep;17(3):321-331. doi: 10.1007/s42000-018-0049-x. Epub 2018 Jul 16. PubMed 30014320 ↗
  • Prado CM, Purcell SA, Laviano A. Nutrition interventions to treat low muscle mass in cancer. J Cachexia Sarcopenia Muscle. 2020 Apr;11(2):366-380. doi: 10.1002/jcsm.12525. Epub 2020 Jan 8. PubMed 31916411 ↗
  • Kyle UG, Schutz Y, Dupertuis YM, Pichard C. Body composition interpretation. Contributions of the fat-free mass index and the body fat mass index. Nutrition. 2003 Jul-Aug;19(7-8):597-604. doi: 10.1016/s0899-9007(03)00061-3. PubMed 12831945 ↗
  • Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-Ray absorptiometry body composition reference values from NHANES. PLoS One. 2009 Sep 15;4(9):e7038. doi: 10.1371/journal.pone.0007038. PubMed 19753111 ↗
  • Liu P, Ma F, Lou H, Liu Y. The utility of fat mass index vs. body mass index and percentage of body fat in the screening of metabolic syndrome. BMC Public Health. 2013 Jul 3;13:629. doi: 10.1186/1471-2458-13-629. PubMed 23819808 ↗
  • Bilen MA, Martini DJ, Liu Y, Lewis C, Collins HH, Shabto JM, Akce M, Kissick HT, Carthon BC, Shaib WL, Alese OB, Pillai RN, Steuer CE, Wu CS, Lawson DH, Kudchadkar RR, El-Rayes BF, Master VA, Ramalingam SS, Owonikoko TK, Harvey RD. The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy. Cancer. 2019 Jan 1;125(1):127-134. doi: 10.1002/cncr.31778. Epub 2018 Oct 17. PubMed 30329148 ↗
  • Charuhas Macris P, Schilling K, Palko R. Academy of Nutrition and Dietetics: Revised 2017 Standards of Practice and Standards of Professional Performance for Registered Dietitian Nutritionists (Competent, Proficient, and Expert) in Oncology Nutrition. J Acad Nutr Diet. 2018 Apr;118(4):736-748.e42. doi: 10.1016/j.jand.2018.01.012. PubMed 29576093 ↗
  • Heymsfield SB, Gonzalez MC, Lu J, Jia G, Zheng J. Skeletal muscle mass and quality: evolution of modern measurement concepts in the context of sarcopenia. Proc Nutr Soc. 2015 Nov;74(4):355-66. doi: 10.1017/S0029665115000129. Epub 2015 Apr 8. PubMed 25851205 ↗
  • Krenitsky J. Adjusted body weight, pro: evidence to support the use of adjusted body weight in calculating calorie requirements. Nutr Clin Pract. 2005 Aug;20(4):468-73. doi: 10.1177/0115426505020004468. PubMed 16207686 ↗
  • Renzi C, Kaushal A, Emery J, Hamilton W, Neal RD, Rachet B, Rubin G, Singh H, Walter FM, de Wit NJ, Lyratzopoulos G. Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms. Nat Rev Clin Oncol. 2019 Dec;16(12):746-761. doi: 10.1038/s41571-019-0249-6. Epub 2019 Jul 26. PubMed 31350467 ↗
  • da Silva JR Jr, Wiegert EVM, Oliveira L, Calixto-Lima L. Different methods for diagnosis of sarcopenia and its association with nutritional status and survival in patients with advanced cancer in palliative care. Nutrition. 2019 Apr;60:48-52. doi: 10.1016/j.nut.2018.09.003. Epub 2018 Sep 15. PubMed 30529186 ↗
  • Charan J, Biswas T. How to calculate sample size for different study designs in medical research? Indian J Psychol Med. 2013 Apr;35(2):121-6. doi: 10.4103/0253-7176.116232. PubMed 24049221 ↗
  • Ramos Chaves M, Boleo-Tome C, Monteiro-Grillo I, Camilo M, Ravasco P. The diversity of nutritional status in cancer: new insights. Oncologist. 2010;15(5):523-30. doi: 10.1634/theoncologist.2009-0283. Epub 2010 Apr 15. PubMed 20395552 ↗
  • Malard F, Mohty M. Acute lymphoblastic leukaemia. Lancet. 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1. PubMed 32247396 ↗
  • Murphy-Alford AJ, Prasad M, Slone J, Stein K, Mosby TT. Perspective: Creating the Evidence Base for Nutritional Support in Childhood Cancer in Low- and Middle-Income Countries: Priorities for Body Composition Research. Adv Nutr. 2020 Mar 1;11(2):216-223. doi: 10.1093/advances/nmz095. PubMed 31529044 ↗
  • Murphy AJ, White M, Viani K, Mosby TT. Evaluation of the nutrition screening tool for childhood cancer (SCAN). Clin Nutr. 2016 Feb;35(1):219-224. doi: 10.1016/j.clnu.2015.02.009. Epub 2015 Feb 21. PubMed 25765336 ↗
  • Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017 Jun 30;7(6):e577. doi: 10.1038/bcj.2017.53. PubMed 28665419 ↗
  • Mosby TT, Romero AL, Linares AL, Challinor JM, Day SW, Caniza M. Testing efficacy of teaching food safety and identifying variables that affect learning in a low-literacy population. J Cancer Educ. 2015 Mar;30(1):100-7. doi: 10.1007/s13187-014-0666-2. PubMed 24781933 ↗
  • Barr RD, Stevens MCG. The influence of nutrition on clinical outcomes in children with cancer. Pediatr Blood Cancer. 2020 Jun;67 Suppl 3:e28117. doi: 10.1002/pbc.28117. Epub 2020 Mar 5. PubMed 32134218 ↗
  • Srivastava R, Batra A, Dhawan D, Bakhshi S. Association of energy intake and expenditure with obesity: A cross-sectional study of 150 pediatric patients following treatment for leukemia. Pediatr Hematol Oncol. 2017 Feb;34(1):29-35. doi: 10.1080/08880018.2016.1272025. Epub 2017 Mar 13. PubMed 28287332 ↗
  • Totadri S, Trehan A, Mahajan D, Viani K, Barr R, Ladas EJ. Validation of an algorithmic nutritional approach in children undergoing chemotherapy for cancer. Pediatr Blood Cancer. 2019 Dec;66(12):e27980. doi: 10.1002/pbc.27980. Epub 2019 Aug 28. PubMed 31464100 ↗
  • Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, Fearon K, Hutterer E, Isenring E, Kaasa S, Krznaric Z, Laird B, Larsson M, Laviano A, Muhlebach S, Muscaritoli M, Oldervoll L, Ravasco P, Solheim T, Strasser F, de van der Schueren M, Preiser JC. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017 Feb;36(1):11-48. doi: 10.1016/j.clnu.2016.07.015. Epub 2016 Aug 6. PubMed 27637832 ↗
  • Ladas EJ, Arora B, Howard SC, Rogers PC, Mosby TT, Barr RD. A Framework for Adapted Nutritional Therapy for Children With Cancer in Low- and Middle-Income Countries: A Report From the SIOP PODC Nutrition Working Group. Pediatr Blood Cancer. 2016 Aug;63(8):1339-48. doi: 10.1002/pbc.26016. Epub 2016 Apr 15. PubMed 27082376 ↗
  • Jansen H, Postma A, Stolk RP, Kamps WA. Acute lymphoblastic leukemia and obesity: increased energy intake or decreased physical activity? Support Care Cancer. 2009 Jan;17(1):103-6. doi: 10.1007/s00520-008-0531-0. Epub 2008 Nov 7. PubMed 18989711 ↗
  • Fuemmeler BF, Pendzich MK, Clark K, Lovelady C, Rosoff P, Blatt J, Demark-Wahnefried W. Diet, physical activity, and body composition changes during the first year of treatment for childhood acute leukemia and lymphoma. J Pediatr Hematol Oncol. 2013 Aug;35(6):437-43. doi: 10.1097/MPH.0b013e318279cd3e. PubMed 23211695 ↗
  • Iughetti L, Bruzzi P, Predieri B, Paolucci P. Obesity in patients with acute lymphoblastic leukemia in childhood. Ital J Pediatr. 2012 Jan 27;38:4. doi: 10.1186/1824-7288-38-4. PubMed 22284631 ↗
  • Butturini AM, Dorey FJ, Lange BJ, Henry DW, Gaynon PS, Fu C, Franklin J, Siegel SE, Seibel NL, Rogers PC, Sather H, Trigg M, Bleyer WA, Carroll WL. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007 May 20;25(15):2063-9. doi: 10.1200/JCO.2006.07.7792. PubMed 17513811 ↗
  • Woolcott OO, Bergman RN. Relative Fat Mass as an estimator of whole-body fat percentage among children and adolescents: A cross-sectional study using NHANES. Sci Rep. 2019 Oct 24;9(1):15279. doi: 10.1038/s41598-019-51701-z. PubMed 31649287 ↗
  • Atherton RR, Williams JE, Wells JC, Fewtrell MS. Use of fat mass and fat free mass standard deviation scores obtained using simple measurement methods in healthy children and patients: comparison with the reference 4-component model. PLoS One. 2013 May 17;8(5):e62139. doi: 10.1371/journal.pone.0062139. Print 2013. PubMed 23690932 ↗
  • Tan SY, Poh BK, Nadrah MH, Jannah NA, Rahman J, Ismail MN. Nutritional status and dietary intake of children with acute leukaemia during induction or consolidation chemotherapy. J Hum Nutr Diet. 2013 Jul;26 Suppl 1:23-33. doi: 10.1111/jhn.12074. Epub 2013 May 24. PubMed 23701375 ↗
  • Murphy AJ, White M, Davies PS. Body composition of children with cancer. Am J Clin Nutr. 2010 Jul;92(1):55-60. doi: 10.3945/ajcn.2010.29201. Epub 2010 May 19. PubMed 20484453 ↗
  • Rogers PC, Barr RD. The relevance of nutrition to pediatric oncology: A cancer control perspective. Pediatr Blood Cancer. 2020 Jun;67 Suppl 3:e28213. doi: 10.1002/pbc.28213. Epub 2020 Feb 25. PubMed 32096351 ↗
  • Ding YY, Ramakrishna S, Long AH, Phillips CA, Montiel-Esparza R, Diorio CJ, Bailey LC, Maude SL, Aplenc R, Batra V, Reilly AF, Rheingold SR, Lacayo NJ, Sakamoto KM, Hunger SP. Delayed cancer diagnoses and high mortality in children during the COVID-19 pandemic. Pediatr Blood Cancer. 2020 Sep;67(9):e28427. doi: 10.1002/pbc.28427. Epub 2020 Jun 26. No abstract available. PubMed 32588960 ↗
  • Mehta NM, Corkins MR, Lyman B, Malone A, Goday PS, Carney LN, Monczka JL, Plogsted SW, Schwenk WF; American Society for Parenteral and Enteral Nutrition Board of Directors. Defining pediatric malnutrition: a paradigm shift toward etiology-related definitions. JPEN J Parenter Enteral Nutr. 2013 Jul;37(4):460-81. doi: 10.1177/0148607113479972. Epub 2013 Mar 25. PubMed 23528324 ↗
  • Bauer J, Jurgens H, Fruhwald MC. Important aspects of nutrition in children with cancer. Adv Nutr. 2011 Mar;2(2):67-77. doi: 10.3945/an.110.000141. Epub 2011 Mar 10. PubMed 22332035 ↗
  • Rogers PC, Melnick SJ, Ladas EJ, Halton J, Baillargeon J, Sacks N; Children's Oncology Group (COG) Nutrition Committee. Children's Oncology Group (COG) Nutrition Committee. Pediatr Blood Cancer. 2008 Feb;50(2 Suppl):447-50; discussion 451. doi: 10.1002/pbc.21414. PubMed 18064639 ↗
  • Redondo-Del-Rio MP, Camina-Martin MA, Marugan-de-Miguelsanz JM, de-Mateo-Silleras B. Bioelectrical impedance vector reference values for assessing body composition in a Spanish child and adolescent population. Am J Hum Biol. 2017 Jul 8;29(4). doi: 10.1002/ajhb.22978. Epub 2017 Feb 6. PubMed 28168808 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Aug 2024, 19 months.

Of 1,981 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's 19 months is below that.

Counting every sponsor, half of 2,056 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2021
First posted
Feb 21, 2021
StartActual
Jan 30, 2023
Primary completionActual
Aug 30, 2024
CompletionActual
Nov 30, 2024
Last update
Dec 6, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04764695
Lead sponsor
Universidad de Sonora
Collaborators
International Atomic Energy Agency, Hospital Civil de Guadalajara, Centro de Investigación en Alimentación y Desarrollo A.C.
Responsible party
Verónica López Teros, PhD (Principal Investigator, Clinical Professor, Universidad de Sonora) — Principal investigator
First posted
Feb 21, 2021
Start date
Jan 30, 2023
Primary completion
Aug 30, 2024
Completion
Nov 30, 2024
Last update
Dec 6, 2024

Study contacts

Veronica López Teros, PhD
study director · Universidad de Sonora

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion